Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults
Hiroyuki Mano and colleagues report fusions involving DUX4 in 16.4% of Ph-negative adolescent and young adult acute lymphoblastic leukemia (AYA-ALL) cases. Transplantation assays in mice support an oncogenic role for the DUX4-IGH fusion gene, which expresses DUX4 protein with an aberrant C terminus...
Saved in:
Published in: | Nature genetics Vol. 48; no. 5; pp. 569 - 574 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
New York
Nature Publishing Group US
01-05-2016
Nature Publishing Group |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Hiroyuki Mano and colleagues report fusions involving
DUX4
in 16.4% of Ph-negative adolescent and young adult acute lymphoblastic leukemia (AYA-ALL) cases. Transplantation assays in mice support an oncogenic role for the
DUX4-IGH
fusion gene, which expresses DUX4 protein with an aberrant C terminus at high levels in patients with AYA-ALL.
The oncogenic mechanisms underlying acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA; 15–39 years old) remain largely elusive
1
,
2
,
3
. Here we have searched for new oncogenes in AYA-ALL by performing RNA-seq analysis of Philadelphia chromosome (Ph)-negative AYA-ALL specimens (
n
= 73) with the use of a next-generation sequencer. Interestingly, insertion of D4Z4 repeats containing the
DUX4
gene into the
IGH
locus was frequently identified in B cell AYA-ALL, leading to a high level of expression of DUX4 protein with an aberrant C terminus. A transplantation assay in mice demonstrated that expression of
DUX4
-
IGH
in pro-B cells was capable of generating B cell leukemia
in vivo
.
DUX4
fusions were preferentially detected in the AYA generation. Our data thus show that
DUX4
can become an oncogenic driver as a result of somatic chromosomal rearrangements and that AYA-ALL may be a clinical entity distinct from ALL at other ages. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Commentary-1 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 1061-4036 1546-1718 |
DOI: | 10.1038/ng.3535 |